The DOJ’s generics price fixing probe has been playing out for years, and this week authorities unveiled a new settlement with the small drugmaker Rising Pharmaceuticals. Rising admitted to price fixing and working with a competitor to rig the market for its hypertension med. It also agreed to cooperate in an ongoing criminal investigation.
More: DOJ inks price fixing settlement with small generics player. Will others follow?